Abstract Background Direct-acting antivirals (DAAs) are current standard of HCV treatment (Rx). However, data remain lacking on real-world safety, patterns of biochemical, virologic responses, and sustained virologic response (SVR12) rate in geriatric patients. Aims The present study assessed clinical presentation, safety, SVR12 rate, dynamic changes in HCV...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου